yttrium radioisotopes has been researched along with Disease Exacerbation in 87 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (1.15) | 18.2507 |
| 2000's | 23 (26.44) | 29.6817 |
| 2010's | 53 (60.92) | 24.3611 |
| 2020's | 10 (11.49) | 2.80 |
| Authors | Studies |
|---|---|
| Baum, RP; Chen, X; Kulkarni, HR; Liu, Q; Schuchardt, C; Zhang, J; Zhao, T; Zhu, Z | 1 |
| Aarts, BM; Beets-Tan, RGH; Deroose, CMALO; Dresen, RC; Klompenhouwer, EG; Maleux, G; Neven, P; Punie, K; Wildiers, H | 1 |
| Brennan, VK; Colaone, F; Guardiola, L; Pollock, RF; Shergill, S | 1 |
| Affonso, BB; Carvalho, VO; Falsarella, PM; Ferraz-Neto, BH; Galastri, FL; Garcia, RG; Motta-Leal-Filho, JMD; Nasser, F; Rezende, MB; Valle, LGM | 1 |
| Benson, AB; Gabr, A; Gates, VL; Lewandowski, RJ; Mackey, RV; Miller, FH; Riaz, A; Salem, R; Su, YK; Yaghmai, V | 1 |
| Brzozowski, K; Budzyńska, A; Dziuk, M; Korniluk, J; Mazurek, A; Narloch, J; Piasecki, P; Zięcina, P | 1 |
| Gál, T; Hangody, L; Mikó, I; Szerb, I | 1 |
| Anderson, TM; Cai, K; Knuttinen, MG; Kumar, N; Lu, H; Lu, Y; Mehta, R | 1 |
| Abbott, AM; Choi, J; Doepker, MP; Gandle, C; Kim, Y; Perez, MC; Shridhar, R; Thomas, KL; Zager, JS | 1 |
| Brunson, C; Hennemeyer, CT; Kuo, PH; McGregor, H; McNiel, D; Patel, MV; Woodhead, G | 1 |
| Dagher, NN; Gu, P; Hickey, RM; Park, JS; Ruohoniemi, D; Shanbhogue, KP; Taslakian, B; Wei, J; Welling, TH; Zhan, C | 1 |
| Choi, J; El-Haddad, G; Frakes, J; Kayaleh, R; Kis, B; Krzyston, H; Naziri, J; Parikh, N; Rishi, A; Sweeney, J | 1 |
| Aaltonen, ET; Hickey, RM; Horn, JC; Kulkarni, K; Ruohoniemi, DM; Taslakian, B; Wei, J; Zhan, C | 1 |
| Bishay, V; Cedillo, M; Charles, D; Fischman, A; Kim, E; Lookstein, R; Marinelli, B; Marron, T; Murthy, S; Nowakowski, S; Pasik, SD; Patel, RS; Ranade, M; Schwartz, M; Sung, M | 1 |
| Boike, JR; Borja-Cacho, D; Caicedo-Ramirez, JC; Christopher, DA; Flamm, SL; Gabr, A; Ganger, DR; Gordon, AC; Gupta, AN; Katariya, NN; Kulik, LM; Ladner, DP; Lewandowski, RJ; Maddur, H; Moore, CM; Riaz, A; Salem, R; Thornburg, BG | 1 |
| Bhattacharya, R; Harris, WP; Hippe, DS; Horton, KJ; Ingraham, CR; Johnson, GE; Kogut, MJ; Kwan, S; Monsky, WL; Padia, SA; Park, JO; Vaidya, S | 1 |
| Golzarian, J; Young, S | 1 |
| Deltenre, P; Denys, A; Duran, R | 1 |
| Aguilar-Rodríguez, M; Bonanad, S; Carrasco, JJ; Pérez-Alenda, S; Querol, F; Querol-Giner, M | 1 |
| Devereaux, K; Louie, JD; Poultsides, GA; Titan, AL | 1 |
| Benito, A; Chopitea, A; Iñarrairaegui, M; Jaureguizar, JIB; Páramo, M; Rodríguez-Fraile, M; Sancho, L; Sangro, B | 1 |
| Al-Nahhas, A; Alsafi, A; Braat, AJAT; Clift, AK; Drymousis, P; Frilling, A; Habib, N; Tait, PN; Thomas, R; Wasan, HS | 1 |
| Akhter, N; Brower, J; Frantz, S; Kim, AY | 1 |
| Bell, JK; Carolan-Rees, G; Crellin, A; Dale, M; Manas, DM; Patrick, HE; See, TC; Sharma, RA; Slevin, NJ; White, J | 1 |
| Chen, YF; Gaba, RC; Guzman, G; Huang, YH; Lokken, RP; Park, BV | 1 |
| Atassi, R; Ganger, D; Gupta, R; Kulik, L; Lewandowski, RJ; Memon, K; Miller, FH; Mulcahy, MF; Ryu, RK; Salem, R; Vouche, M | 1 |
| Boucher, E; Boudjema, K; Boulic, A; Clément, B; Edeline, J; Garin, E; Le Du, F; Lenoir, L; Pracht, M; Raoul, JL; Rolland, Y | 1 |
| Baker, T; Benson, AB; Gupta, R; Lewandowski, RJ; Memon, K; Mouli, S; Mulcahy, MF; Ryu, RK; Salem, R | 1 |
| Chen, PJ; Cheng, SQ; Chow, P; Han, KH; Lau, WY; Lee, RC; Leung, T; Poon, RT; Sangro, B | 1 |
| Abecassis, M; Atassi, R; Baker, T; Caicedo, JC; Fryer, J; Gaba, RC; Ganger, D; Gates, VL; Hickey, R; Kulik, L; Lewandowski, RJ; Memon, K; Mulcahy, MF; Riaz, A; Ryu, RK; Salem, R; Sato, K; Vouche, M | 1 |
| Choo, SP; Chow, PK; Gandhi, M; Goh, AS; Han, HS; Khin, MW; Lai, HK; Lim, TG; Lo, RH; Poon, DY; Singh, H; Soo, KC; Tan, SB; Tay, KH | 1 |
| Abecassis, M; Baker, T; Caicedo, JC; Fryer, J; Ganger, D; Habib, A; Hickey, R; Hohlastos, E; Kim, E; Kulik, L; Lewandowski, RJ; Mulcahy, M; Salem, R; Sato, KT; Vouche, M; Ward, TJ | 1 |
| Coveler, A; Harris, WP; Kwan, SW; Monsky, WL; Padia, SA; Roudsari, B | 1 |
| Berkova, Z; Braun, FK; Fanale, MA; Feng, L; Fowler, N; Kwak, LW; Mathur, R; McLaughlin, P; Neelapu, SS; Pro, B; Romaguera, JE; Samaniego, F; Sehgal, L; Selvaraj, V; Shah, JJ | 1 |
| Goldenberg, DM; Kio, EA; Misleh, JG; Sharkey, RM; Tomblyn, MB; Wegener, WA; Witzig, TE | 1 |
| Gates, VL; Gordon, AC; Gradishar, WJ; Kaklamani, VG; Lewandowski, RJ; Ryu, RK; Salem, R; Sato, KT; Thuluvath, AJ | 1 |
| Abdel-Rehim, M; Castéra, L; Chatellier, G; Lebtahi, R; Ronot, M; Sibert, A; Vilgrain, V | 1 |
| Camacho, JC; El-Rayes, BF; Kim, HS; Knechtle, SJ; Kokabi, N; Spivey, JR; Xing, M | 1 |
| Bahary, N; Braiteh, FS; Bridges, BB; Cohen, SJ; Conkling, PR; Dragovich, T; Frank, RC; Goldenberg, DM; Goldsmith, SJ; Gribbin, TE; Guarino, MJ; Horne, H; Intenzo, CM; Korn, RL; Lee, FC; Lee, M; Lowery, MA; Manzone, TC; Mitchel, EP; O'Neil, BH; O'Reilly, EM; Ocean, AJ; Pandit-Taskar, N; Picozzi, VJ; Ramanathan, RK; Richards, DA; Sharkey, RM; Sheikh, A; Starodub, AN; Von Hoff, DD; Wegener, WA | 1 |
| Albert, NL; Bartenstein, P; Boeck, S; Fendler, WP; Heinemann, V; Ilhan, H; Lehner, S; Michl, M; Paprottka, PM | 1 |
| Alshebeeb, K; Biederman, DM; Facciuto, ME; Fischman, AM; Florman, S; Gunasekaran, G; Kim, E; Nowakowski, FS; Patel, RS; Pierobon, ES; Schwartz, M; Tabori, NE; Titano, JJ | 1 |
| Han, KH; Kim, DY | 1 |
| Ahmadzadehfar, H; Block, W; Meyer, C; Nadal, J; Pieper, CC; Schild, HH; Wilhelm, KE; Willinek, WA | 1 |
| Gordon, AC; Lewandowski, RJ; Salem, R | 1 |
| Abecassis, M; Baker, T; Benson, AB; Desai, K; Gabr, A; Ganger, D; Gordon, AC; Hickey, R; Kallini, J; Kulik, L; Lewandowski, RJ; Miller, FH; Mouli, S; Mulcahy, MF; Rademaker, A; Salem, R; Sato, K; Thornburg, B; Yaghmai, V | 1 |
| Bhoori, S; Ciani, O; Facciorusso, A; Mazzaferro, V; Rognoni, C; Sommariva, S; Tarricone, R | 1 |
| Ardill, JE; Eatock, M; Johnston, BT; McCance, DR | 1 |
| Dhanasekaran, R; Kim, HS; Knechtle, SJ; Parekh, S; Sakaria, S; Spivey, J; Xing, M; Zhang, D | 1 |
| Abuodeh, Y; Ahmed, KA; Anaya, DA; Biebel, B; Choi, J; El-Haddad, G; Frakes, JM; Hoffe, SE; Kim, R; Kim, Y; Kis, B; Malafa, M; Naghavi, AO; Sweeney, J; Venkat, PS | 1 |
| Abecassis, M; Baker, T; Ibrahim, SM; Kulik, LM; Lewandowski, RJ; Miller, FH; Mulcahy, MF; Omary, R; Riaz, A; Ryu, RK; Salem, R; Sato, KT; Senthilnathan, S | 1 |
| Cianni, R; Cortesi, E; Dornbusch, T; Notarianni, E; Pasqualini, V; Saltarelli, A; Salvatori, R; Urigo, C | 1 |
| Dreyling, M; Gisselbrecht, C; Gregory, SA; Hohloch, K; Tobinai, K | 1 |
| Buscombe, JR; Cwikla, JB; Jeziorski, KG; Mikolajczak, R; Nasierowska-Guttmejer, A; Pawlak, D; Sankowski, A; Seklecka, N; Stepien, K; Walecki, J | 1 |
| Alegre, F; Arbizu, J; Benito, A; Bilbao, JI; D'Avola, D; Herrero, JI; Iñarrairaegui, M; Martinez-Cuesta, A; Prieto, J; Quiroga, J; Rodríguez, M; Sangro, B | 1 |
| Doros, A | 1 |
| Abecassis, M; Atassi, B; Baker, T; Benson, AB; Carr, J; Chen, R; Chrisman, HB; Gates, VL; Gupta, R; Ibrahim, SM; Kulik, L; Lewandowski, RJ; Memon, K; Miller, FH; Mulcahy, MF; Nemcek, AA; Newman, S; Nikolaidis, P; Omary, RA; Resnick, SA; Riaz, A; Ryu, RK; Salem, R; Sato, KT; Senthilnathan, S; Vogelzang, RL; Wang, E; Yaghmai, V | 1 |
| Applebaum, L; Barak, D; Eckstein, J; Fraenkel, M; Gross, DJ; Grozinsky-Glasberg, S; Müeller-Brand, J; Shimon, I; Walter, MA | 1 |
| Bamberg, F; Dürr, EM; Haug, A; Helmberger, TK; Hoffmann, RT; Jakobs, TF; Kolligs, FT; Paprottka, PM; Rauch, B; Reiser, MF; Schön, A; Trumm, CT | 1 |
| Baete, K; Deroose, CM; Haustermans, K; Koole, M; Mortelmans, L; Mottaghy, FM; Terwinghe, C; Van Binnebeek, S; Van Cutsem, E; Vanbilloen, B; Verbruggen, A; Verslype, C | 1 |
| Głowa, B; Hubalewska-Dydejczyk, AB; Jabrocka-Hybel, A; Królicki, L; Kunikowska, J; Mikołajczak, R; Pach, D; Pawlak, D; Sowa-Staszczak, A; Stefańska, A; Tomaszuk, M; Trofimiuk, M | 1 |
| Abecassis, M; Baker, T; Ibrahim, SM; Kulik, L; Lewandowski, RJ; Mulcahy, MF; Ryu, RK; Salem, R | 1 |
| Abdelmaksoud, MH; Hwang, GL; Kothary, N; Louie, JD; Minor, DR; Sze, DY | 1 |
| Bagni, O; Cianni, R; Cortesi, E; Filippi, L; Notarianni, E; Pelle, G; Rabuffi, P; Saltarelli, A | 1 |
| Al Younis, I; Coenraad, MJ; Defreyne, L; Lam, MG; Lambert, B; Seinstra, BA; van den Bosch, MA; van Erkel, AR; van Erpecum, KJ; van Hoek, B; van Vlierberghe, H; Verkooijen, HM | 1 |
| Benson, AB; Ganger, D; Gates, VL; Gupta, R; Kulik, L; Lewandowski, RJ; Memon, K; Miller, FH; Mulcahy, MF; Omary, RA; Riaz, A; Salem, R; Vouche, M | 1 |
| Bron, D; de Wind, A; Delatte, P; Flamen, P; Meuleman, N; Muylle, K; Nguyen, J; Roelandts, M; Van der Stappen, A; Vanderlinden, B | 1 |
| Alavi, A; Goldenberg, DM; Hartzell, KB; Klumpp, TR; Luger, SM; Maillard, I; Nasta, SD; Porter, DL; Schuster, SJ; Sharkey, RM; Stadtmauer, EA; Tsai, DE | 1 |
| Bouterfa, H; Bushnell, D; Carlisle, T; Connolly, M; Karwal, M; Madsen, M; Menda, Y; O'Dorisio, T; Parker, S; Ponto, J; Ponto, L; Zehr, P | 1 |
| Darif, M; Emmanouilides, C; Gordon, LI; Molina, A; Raubtischek, A; Schilder, RJ; White, CA; Wiseman, G; Witzig, T | 1 |
| Bander, NH; Goldsmith, SJ; Kostakoglu, L; Milowsky, MI; Nanus, DM; Vallabhajosula, S | 1 |
| Buitrago, C; Herrmann, R; Maecke, H; Mueller-Brand, J; Pless, M; Waldherr, C | 1 |
| Bartlett, N; Czuczman, M; Darif, M; Emmanouilides, C; Gordon, LI; Joyce, R; Molina, A; Pohlman, B; Theuer, C; Vo, K; White, C; Wiseman, G; Witzig, T | 1 |
| Carr, BI; Dancey, JE; Geschwind, JF; Goin, JE; Goin, K; Salem, R; Soulen, MC; Thurston, K; Van Buskirk, M | 1 |
| Wiseman, GA; Witzig, TE | 1 |
| Coleman, M; Furman, RR; Leonard, JP; Ruan, J | 1 |
| Gokhale, AS; Macklis, RM; Mayadev, J; Pohlman, B | 1 |
| Busby, E; Carey, D; Forero, A; Grizzle, WE; Khazaeli, MB; LoBuglio, AF; Meredith, RF; Robert, F; Shen, S | 1 |
| Blau, IW; Fietz, T; Gentilini, C; Glass, B; Marinets, O; Muessig, A; Munz, DL; Rieger, K; Sandrock, D; Thiel, E; Uharek, L | 1 |
| Cheung, MC; Haynes, AE; Imrie, K; Meyer, RM; Stevens, A | 1 |
| Helmberger, T; Hoffmann, RT; Jakobs, TF; Koch, W; Lubiensky, A; Lutz, J; Poepperl, G; Reiser, MF; Schmitz, A; Tatsch, K | 1 |
| Atassi, B; Ibrahim, S; Jakobs, TF; Kulik, LM; Lewandowski, RJ; Miller, F; Mulcahy, MF; Murthy, R; Omary, R; Reda, E; Reiser, MF; Ryu, RK; Saleem, S; Salem, R; Sato, KT; Yaghmai, V | 1 |
| Bodet-Milin, C; Campion, L; Dupas, B; Gastinne, T; Goldenberg, DM; Harousseau, JL; Huglo, D; Kraeber-Bodéré, F; Le Gouill, S; Morschhauser, F; Wegener, WA | 1 |
| Atassi, B; Barakat, O; Benson, A; Gates, VL; Lewandowski, RJ; Mandal, R; Miller, FH; Mulcahy, MF; Nemcek, AA; Newman, SB; Omary, RA; Ryu, RK; Salem, R; Sato, KT; Shaw, JM; Talamonti, M; Thurston, KG; Wong, CY | 1 |
| Galindo, E; López-Cabarcos, C; Magallón, M; Rodríguez-Merchán, EC | 1 |
| Baumgart, D; Calman, F; de Bruyne, B; Disco, C; Kovacs, G; Lins, M; Popowski, Y; Sauerwein, W; Serruys, PW; Thomas, M; Verin, V; Wijns, W | 1 |
| Anderson, J; Burton, M; Gebski, V; Gray, B; Hope, M; Moroz, P; Van Hazel, G | 1 |
| Bartlett, NL; Cabanillas, F; Czuczman, MS; Emmanouilides, C; Gordon, LI; Grillo-López, AJ; Joyce, R; Multani, P; Padre, N; Pohlman, BL; White, CA; Wiseman, GA; Witzig, TE | 1 |
7 review(s) available for yttrium radioisotopes and Disease Exacerbation
| Article | Year |
|---|---|
Radioembolisation with 90Y microspheres for neuroendocrine liver metastases: an institutional case series, systematic review and meta-analysis.
Topics: Aged; Disease Progression; Embolization, Therapeutic; Female; Humans; Liver Neoplasms; Male; Microspheres; Middle Aged; Neuroendocrine Tumors; Progression-Free Survival; Radiopharmaceuticals; Retrospective Studies; Time Factors; Yttrium Radioisotopes | 2019 |
Treatment for hepatocellular carcinoma with portal vein tumor thrombosis: the emerging role for radioembolization using yttrium-90.
Topics: Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Disease Progression; Humans; Ischemia; Liver Neoplasms; Necrosis; Portal Vein; Prognosis; Quality of Life; Risk Factors; Time Factors; Treatment Outcome; Yttrium Radioisotopes | 2013 |
Transarterial chemoembolization versus transarterial radioembolization in hepatocellular carcinoma: optimization of selecting treatment modality.
Topics: Brachytherapy; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Clinical Trials as Topic; Disease Progression; Female; Humans; Liver Neoplasms; Male; Patient Selection; Retrospective Studies; Treatment Outcome; Yttrium Radioisotopes | 2016 |
Trans-arterial radioembolization in intermediate-advanced hepatocellular carcinoma: systematic review and meta-analyses.
Topics: Brachytherapy; Carcinoma, Hepatocellular; Catheters; Chemoembolization, Therapeutic; Chemoradiotherapy; Disease Progression; Humans; Liver Failure; Liver Neoplasms; Neoplasm Staging; Observational Studies as Topic; Portal Vein; Survival Rate; Time Factors; Treatment Outcome; Venous Thrombosis; Yttrium Radioisotopes | 2016 |
[Interventional radiological treatment of hepatocellular carcinoma].
Topics: Carcinoma, Hepatocellular; Disease Progression; Humans; Liver Neoplasms; Microspheres; Radiology, Interventional; Tomography, X-Ray Computed; Treatment Outcome; Yttrium Radioisotopes | 2010 |
New developments in immunotherapy for non-Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Agents; Combined Modality Therapy; Disease Progression; Humans; Immunotherapy; Interleukin-2; Lymphoma; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Radioimmunotherapy; Rituximab; Yttrium Radioisotopes | 2005 |
Yttrium 90 ibritumomab tiuxetan in lymphoma.
Topics: Antibodies, Monoclonal; Clinical Trials as Topic; Disease Progression; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Quality of Life; Radioimmunotherapy; Radiometry; Treatment Outcome; Yttrium Radioisotopes | 2006 |
21 trial(s) available for yttrium radioisotopes and Disease Exacerbation
| Article | Year |
|---|---|
Multicenter phase II study of sequential radioembolization-sorafenib therapy for inoperable hepatocellular carcinoma.
Topics: Aged; Carcinoma, Hepatocellular; Disease Progression; Dose-Response Relationship, Drug; Embolization, Therapeutic; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Quality of Life; Sorafenib; Time Factors; Yttrium Radioisotopes | 2014 |
90Y-ibritumomab tiuxetan radiotherapy as first-line therapy for early stage low-grade B-cell lymphomas, including bulky disease.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Disease Progression; Female; Follow-Up Studies; Hematologic Diseases; Humans; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Radiation Injuries; Radioimmunotherapy; Survival Analysis; Treatment Outcome; Yttrium Radioisotopes | 2014 |
Anti-CD22 90Y-epratuzumab tetraxetan combined with anti-CD20 veltuzumab: a phase I study in patients with relapsed/refractory, aggressive non-Hodgkin lymphoma.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone Marrow; Disease Progression; Female; Humans; Indium Radioisotopes; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Positron-Emission Tomography; Radioimmunotherapy; Tomography, X-Ray Computed; Treatment Outcome; Yttrium Radioisotopes | 2014 |
Radioembolisation with yttrium‒90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): study protocol for a randomised controlled trial.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Clinical Protocols; Cost-Benefit Analysis; Disease Progression; Disease-Free Survival; Drug Costs; Embolization, Therapeutic; France; Humans; Liver Neoplasms; Microspheres; Niacinamide; Phenylurea Compounds; Prospective Studies; Protein Kinase Inhibitors; Quality of Life; Research Design; Sorafenib; Time Factors; Treatment Outcome; Yttrium Radioisotopes | 2014 |
Open-label prospective study of the safety and efficacy of glass-based yttrium 90 radioembolization for infiltrative hepatocellular carcinoma with portal vein thrombosis.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Disease Progression; Embolization, Therapeutic; Female; Humans; Liver Neoplasms; Male; Middle Aged; Portal Vein; Prognosis; Prospective Studies; Treatment Outcome; Venous Thrombosis; Yttrium Radioisotopes | 2015 |
(90)Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Feasibility Studies; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Mucins; Pancreatic Neoplasms; Radioimmunotherapy; Radiopharmaceuticals; Remission Induction; Thrombocytopenia; Time Factors; Treatment Outcome; United States; Yttrium Radioisotopes | 2015 |
Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Diarrhea; Disease Progression; Disease-Free Survival; Ethiodized Oil; Female; Humans; Hypoalbuminemia; Intention to Treat Analysis; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Necrosis; Neoplasm Staging; Prospective Studies; Survival Rate; Yttrium Radioisotopes | 2016 |
Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a phase II study.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Neuroendocrine; Disease Progression; Female; Gastrointestinal Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Octreotide; Organometallic Compounds; Pancreatic Neoplasms; Radionuclide Imaging; Treatment Outcome; Young Adult; Yttrium Radioisotopes | 2010 |
Transarterial radioembolization versus chemoembolization for the treatment of hepatocellular carcinoma (TRACE): study protocol for a randomized controlled trial.
Topics: Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Cost-Benefit Analysis; Disease Progression; Embolization, Therapeutic; Health Care Costs; Hepatic Artery; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Magnetic Resonance Imaging; Microspheres; Netherlands; Quality of Life; Radiography; Radiopharmaceuticals; Research Design; Time Factors; Treatment Outcome; Yttrium Radioisotopes | 2012 |
Assessment of hepatic toxicity from treatment with 90Y-SMT 487 (OctreoTher(TM)) in patients with diffuse somatostatin receptor positive liver metastases.
Topics: Alanine Transaminase; Alkaline Phosphatase; Analysis of Variance; Aspartate Aminotransferases; Carcinoma, Neuroendocrine; Clinical Protocols; Disease Progression; Humans; Liver; Liver Neoplasms; Octreotide; Radiopharmaceuticals; Receptors, Somatostatin; Somatostatin; Tomography, Emission-Computed, Single-Photon; Yttrium Radioisotopes | 2003 |
Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study.
Topics: Antibodies, Monoclonal; Antigens, CD; Antigens, CD20; Disease Progression; Disease-Free Survival; Follow-Up Studies; Humans; Lymphoma, B-Cell; Radioimmunotherapy; Time Factors; Yttrium Radioisotopes | 2004 |
Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer.
Topics: Aged; Aged, 80 and over; Androgens; Antibodies, Monoclonal; Antigens, Surface; Disease Progression; Drug Resistance, Neoplasm; Glutamate Carboxypeptidase II; Humans; Male; Maximum Tolerated Dose; Middle Aged; Prostatic Neoplasms; Radionuclide Imaging; Yttrium Radioisotopes | 2004 |
Targeted radiotherapy for small cell lung cancer using 90Yttrium-DOTATOC, an Yttrium-labelled somatostatin analogue: a pilot trial.
Topics: Aged; Carcinoma, Small Cell; Disease Progression; Disease-Free Survival; Female; Humans; Lung Neoplasms; Male; Middle Aged; Octreotide; Radionuclide Imaging; Radiopharmaceuticals; Yttrium Radioisotopes | 2004 |
Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Agents; Cell Line, Transformed; Clinical Trials as Topic; Disease Progression; Follow-Up Studies; Humans; Lymphoma, B-Cell; Lymphoma, Follicular; Radioimmunotherapy; Remission Induction; Rituximab; Time Factors; Treatment Outcome; Yttrium Radioisotopes | 2004 |
Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: factors associated with liver toxicities.
Topics: Aged; Bilirubin; Brachytherapy; Carcinoma, Hepatocellular; Disease Progression; Female; Follow-Up Studies; Hepatic Artery; Humans; Injections, Intra-Arterial; Liver; Liver Cirrhosis; Liver Neoplasms; Male; Microspheres; Radiopharmaceuticals; Radiotherapy Dosage; Retrospective Studies; Risk Factors; Yttrium Radioisotopes | 2005 |
Phase I study of 90Y-CC49 monoclonal antibody therapy in patients with advanced non-small cell lung cancer: effect of chelating agents and paclitaxel co-administration.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Neoplasm; Antigens, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chelating Agents; Clinical Trials as Topic; Disease Progression; Edetic Acid; Female; Glycoproteins; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Paclitaxel; Pentetic Acid; Radioimmunotherapy; Radiometry; Thrombocytopenia; Treatment Outcome; Up-Regulation; Yttrium Radioisotopes | 2005 |
Fibrosis, portal hypertension, and hepatic volume changes induced by intra-arterial radiotherapy with 90yttrium microspheres.
Topics: Disease Progression; Dose-Response Relationship, Radiation; Embolization, Therapeutic; Female; Humans; Hypertension, Portal; Liver; Liver Cirrhosis; Liver Neoplasms; Male; Microspheres; Organ Size; Radiation Injuries; Radiotherapy; Treatment Outcome; Yttrium Radioisotopes | 2008 |
Evaluation of response to fractionated radioimmunotherapy with 90Y-epratuzumab in non-Hodgkin's lymphoma by 18F-fluorodeoxyglucose positron emission tomography.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, Neoplasm; Disease Progression; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Positron-Emission Tomography; Predictive Value of Tests; Radioimmunotherapy; Radiopharmaceuticals; Salvage Therapy; Sensitivity and Specificity; Sialic Acid Binding Ig-like Lectin 2; Tomography, X-Ray Computed; Treatment Outcome; Yttrium Radioisotopes | 2008 |
Endoluminal beta-radiation therapy for the prevention of coronary restenosis after balloon angioplasty. The Dose-Finding Study Group.
Topics: Aged; Angioplasty, Balloon, Coronary; Beta Particles; Brachytherapy; Combined Modality Therapy; Coronary Angiography; Coronary Disease; Coronary Vessels; Disease Progression; Dose-Response Relationship, Radiation; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Radiotherapy Dosage; Secondary Prevention; Stents; Yttrium Radioisotopes | 2001 |
Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Female; Floxuridine; Hepatic Artery; Humans; Liver Neoplasms; Male; Microspheres; Middle Aged; Quality of Life; Risk Factors; Treatment Outcome; Yttrium Radioisotopes | 2001 |
Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD19; Antineoplastic Agents; Cell Transformation, Neoplastic; Disease Progression; Disease-Free Survival; Female; Humans; Liver; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Middle Aged; Radioimmunotherapy; Radionuclide Imaging; Rituximab; Survival Rate; Treatment Outcome; Yttrium Radioisotopes | 2002 |
59 other study(ies) available for yttrium radioisotopes and Disease Exacerbation
| Article | Year |
|---|---|
Peptide Receptor Radionuclide Therapy in Patients With Advanced Progressive Medullary Thyroid Cancer: Efficacy, Safety, and Survival Predictors.
Topics: Adult; Disease Progression; Female; Humans; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Receptors, Peptide; Retrospective Studies; Thyroid Neoplasms; Yttrium Radioisotopes | 2023 |
Sequential intra-arterial infusion of 90Y-resin microspheres and mitomycin C in chemo refractory liver metastatic breast cancer patients: a single centre pilot study.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Body Surface Area; Breast Neoplasms; Combined Modality Therapy; Disease Progression; Drug Resistance, Neoplasm; Embolization, Therapeutic; Feasibility Studies; Female; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Microspheres; Middle Aged; Mitomycin; Pilot Projects; Prospective Studies; Treatment Outcome; Yttrium Radioisotopes | 2020 |
A cost analysis of SIR-Spheres yttrium-90 resin microspheres versus tyrosine kinase inhibitors in the treatment of unresectable hepatocellular carcinoma in France, Italy, Spain and the UK.
Topics: Brachytherapy; Carcinoma, Hepatocellular; Costs and Cost Analysis; Disease Progression; Europe; Health Expenditures; Health Resources; Humans; Liver Neoplasms; Markov Chains; Microspheres; Models, Econometric; Neoplasm Staging; Patient Acceptance of Health Care; Protein Kinase Inhibitors; Yttrium Radioisotopes | 2020 |
Transarterial radioembolization for liver tumors as neoadjuvant therapy: three case reports.
Topics: Adult; Aged; Bile Duct Neoplasms; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Cholangiocarcinoma; Disease Progression; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Treatment Outcome; Yttrium Radioisotopes | 2020 |
Long-Term Hepatotoxicity of Yttrium-90 Radioembolization as Treatment of Metastatic Neuroendocrine Tumor to the Liver.
Topics: Adult; Aged; Aged, 80 and over; Disease Progression; Embolization, Therapeutic; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neuroendocrine Tumors; Radiation Dosage; Radiology, Interventional; Retrospective Studies; Treatment Outcome; Yttrium Radioisotopes | 2017 |
The Predictive Value of SPECT/CT imaging in colorectal liver metastases response after 90Y-radioembolization.
Topics: Adult; Aged; Colorectal Neoplasms; Disease Progression; Embolization, Therapeutic; Female; Humans; Liver Neoplasms; Male; Middle Aged; Phantoms, Imaging; Radiometry; Single Photon Emission Computed Tomography Computed Tomography; Yttrium Radioisotopes | 2018 |
Effectiveness evaluation of radiosynovectomy on the radiological progression of osteoarthritis of the knee joint.
Topics: Adult; Aged; Disease Progression; Female; Follow-Up Studies; Humans; Knee Joint; Male; Middle Aged; Osteoarthritis, Knee; Radiography; Synovectomy; Synovitis; Young Adult; Yttrium Radioisotopes | 2018 |
A Lesion-Based Response Prediction Model Using Pretherapy PET/CT Image Features for Y90 Radioembolization to Hepatic Malignancies.
Topics: Adult; Aged; Disease Progression; Embolization, Therapeutic; Female; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Imaging, Three-Dimensional; Liver Neoplasms; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Prognosis; Treatment Outcome; Yttrium Radioisotopes | 2017 |
Hepatic Progression-free and Overall Survival After Regional Therapy to the Liver for Metastatic Melanoma.
Topics: Adult; Aged; Aged, 80 and over; Disease Progression; Embolization, Therapeutic; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Melanoma; Melanoma, Cutaneous Malignant; Middle Aged; Prognosis; Retrospective Studies; Skin Neoplasms; Survival Rate; Uveal Neoplasms; Yttrium Radioisotopes | 2018 |
Prior ablation and progression of disease correlate with higher tumor-to-normal liver
Topics: Carcinoma, Hepatocellular; Disease Progression; Embolization, Therapeutic; Humans; Liver Neoplasms; Retrospective Studies; Technetium Tc 99m Aggregated Albumin; Yttrium Radioisotopes | 2023 |
Safety of Combined Yttrium-90 Radioembolization and Immune Checkpoint Inhibitor Immunotherapy for Hepatocellular Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Immunological; Carcinoma, Hepatocellular; Disease Progression; Embolization, Therapeutic; Female; Humans; Immunotherapy; Liver Neoplasms; Male; Middle Aged; Nivolumab; Patient Safety; Progression-Free Survival; Radiopharmaceuticals; Retrospective Studies; Risk Factors; Time Factors; Yttrium Radioisotopes | 2020 |
Transarterial Radioembolization Treatment of Pancreatic Cancer Patients with Liver-Dominant Metastatic Disease Using Yttrium-90 Glass Microspheres: A Single-Institution Retrospective Study.
Topics: Adenocarcinoma; Aged; Disease Progression; Embolization, Therapeutic; Female; Glass; Humans; Male; Microspheres; Middle Aged; Pancreatic Neoplasms; Progression-Free Survival; Radiopharmaceuticals; Retrospective Studies; Time Factors; Yttrium Radioisotopes | 2020 |
Safety and Effectiveness of Yttrium-90 Radioembolization around the Time of Immune Checkpoint Inhibitors for Unresectable Hepatic Metastases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Immunological; Disease Progression; Embolization, Therapeutic; Female; Humans; Liver Neoplasms; Male; Middle Aged; Patient Safety; Progression-Free Survival; Radiopharmaceuticals; Retrospective Studies; Risk Factors; Time Factors; Yttrium Radioisotopes | 2020 |
Safety and Efficacy of Locoregional Treatment during Immunotherapy with Nivolumab for Hepatocellular Carcinoma: A Retrospective Study of 41 Interventions in 29 Patients.
Topics: Adult; Aged; Antineoplastic Agents, Immunological; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Chemotherapy, Adjuvant; Disease Progression; Embolization, Therapeutic; Female; Humans; Liver Neoplasms; Male; Middle Aged; Nivolumab; Radiopharmaceuticals; Retrospective Studies; Time Factors; Treatment Outcome; Yttrium Radioisotopes | 2020 |
Safety and Efficacy of Segmental Yttrium-90 Radioembolization for Hepatocellular Carcinoma after Transjugular Intrahepatic Portosystemic Shunt Creation.
Topics: Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Databases, Factual; Disease Progression; Embolization, Therapeutic; Female; Humans; Liver Neoplasms; Male; Middle Aged; Portasystemic Shunt, Transjugular Intrahepatic; Radiopharmaceuticals; Retrospective Studies; Time Factors; Treatment Outcome; Yttrium Radioisotopes | 2021 |
Segmental Yttrium-90 Radioembolization versus Segmental Chemoembolization for Localized Hepatocellular Carcinoma: Results of a Single-Center, Retrospective, Propensity Score-Matched Study.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Disease Progression; Doxorubicin; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Propensity Score; Radiopharmaceuticals; Retrospective Studies; Survival Rate; Treatment Outcome; Yttrium Radioisotopes | 2017 |
Regarding: Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma.
Topics: Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Disease Progression; Embolization, Therapeutic; Humans; Liver Neoplasms; Treatment Outcome; Yttrium Radioisotopes | 2017 |
RE: Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma.
Topics: Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Disease Progression; Embolization, Therapeutic; Humans; Liver Neoplasms; Treatment Outcome; Yttrium Radioisotopes | 2017 |
Effect of radiosynoviorthesis on the progression of arthropathy and haemarthrosis reduction in haemophilic patients.
Topics: Adolescent; Adult; Ankle Joint; Disease Progression; Elbow Joint; Hemarthrosis; Hemophilia A; Humans; Joint Diseases; Middle Aged; Radioisotopes; Retrospective Studies; Rhenium; Shoulder Joint; Synovectomy; Synovitis; Treatment Outcome; Young Adult; Yttrium Radioisotopes | 2017 |
Clinical Trigonometry: Right Hepatic Trisegmentectomy After Radiation Trisegmentectomy for Hepatocellular Carcinoma.
Topics: Aged; Angiography; Carcinoma, Hepatocellular; Disease Progression; Embolization, Therapeutic; Fatal Outcome; Hepatectomy; Humans; Liver Neoplasms; Male; Neoadjuvant Therapy; Radiography, Interventional; Radiopharmaceuticals; Radiotherapy, Adjuvant; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Yttrium Radioisotopes | 2018 |
Segmental Pneumonitis after Radioembolization.
Topics: Aged; Bile Duct Neoplasms; Cholangiocarcinoma; Computed Tomography Angiography; Disease Progression; Embolization, Therapeutic; Fatal Outcome; Female; Humans; Positron Emission Tomography Computed Tomography; Radiation Pneumonitis; Radiopharmaceuticals; Yttrium Radioisotopes | 2018 |
Radioembolization with Yttrium-90 Microspheres for the Treatment of Liver Metastases of Pancreatic Adenocarcinoma: A Multicenter Analysis.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Disease Progression; Embolization, Therapeutic; Female; Humans; Liver Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Radiopharmaceuticals; Retrospective Studies; Time Factors; Treatment Outcome; United States; Yttrium Radioisotopes | 2019 |
Yttrium-90 Transarterial Radioembolization for Chemotherapy-Refractory Intrahepatic Cholangiocarcinoma: A Prospective, Observational Study.
Topics: Aged; Bile Duct Neoplasms; Cholangiocarcinoma; Disease Progression; Drug Resistance, Neoplasm; Embolization, Therapeutic; England; Female; Humans; Male; Middle Aged; Progression-Free Survival; Prospective Studies; Radiopharmaceuticals; Risk Factors; Time Factors; Yttrium Radioisotopes | 2019 |
Locoregional Therapy of Hepatocellular-Cholangiocarcinoma versus Hepatocellular Carcinoma: A Propensity Score-Matched Study.
Topics: Aged; Bile Duct Neoplasms; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Cholangiocarcinoma; Combined Modality Therapy; Disease Progression; Embolization, Therapeutic; Female; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Progression-Free Survival; Radiofrequency Ablation; Radiopharmaceuticals; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors; Yttrium Radioisotopes | 2019 |
Prospective evaluation of patients with early-/intermediate-stage hepatocellular carcinoma with disease progression following arterial locoregional therapy: candidacy for systemic treatment or clinical trials.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Chi-Square Distribution; Clinical Trials as Topic; Disease Progression; Eligibility Determination; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Patient Selection; Prospective Studies; Radiopharmaceuticals; Time Factors; Treatment Outcome; Yttrium Radioisotopes | 2013 |
Volumetric changes after (90)y radioembolization for hepatocellular carcinoma in cirrhosis: an option to portal vein embolization in a preoperative setting?
Topics: Carcinoma, Hepatocellular; Disease Progression; Embolization, Therapeutic; Female; Humans; Hypertrophy; Liver; Liver Cirrhosis; Liver Neoplasms; Male; Neoadjuvant Therapy; Organ Size; Preoperative Care; Radiotherapy, Adjuvant; Retrospective Studies; Tumor Burden; Yttrium Radioisotopes | 2013 |
Yttrium-90 radioembolization for intrahepatic cholangiocarcinoma: safety, response, and survival analysis.
Topics: Aged; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Disease Progression; Embolization, Therapeutic; Female; Hepatectomy; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Proportional Hazards Models; Radiopharmaceuticals; Radiotherapy, Adjuvant; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome; Yttrium Radioisotopes | 2013 |
Radiation lobectomy: time-dependent analysis of future liver remnant volume in unresectable liver cancer as a bridge to resection.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Disease Progression; Embolization, Therapeutic; Female; Hepatectomy; Humans; Liver; Liver Neoplasms; Magnetic Resonance Imaging; Male; Microspheres; Middle Aged; Organ Size; Survival Rate; Time Factors; Treatment Outcome; Yttrium Radioisotopes | 2013 |
Unresectable solitary hepatocellular carcinoma not amenable to radiofrequency ablation: multicenter radiology-pathology correlation and survival of radiation segmentectomy.
Topics: Aged; Carcinoma, Hepatocellular; Catheter Ablation; Databases, Factual; Disease Progression; Feasibility Studies; Female; Follow-Up Studies; Humans; Liver; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Radiotherapy; Risk Factors; Survival Analysis; Treatment Outcome; Yttrium Radioisotopes | 2014 |
Superselective yttrium-90 radioembolization for hepatocellular carcinoma yields high response rates with minimal toxicity.
Topics: Aged; Angiography, Digital Subtraction; Carcinoma, Hepatocellular; Disease Progression; Embolization, Therapeutic; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Patient Selection; Predictive Value of Tests; Radiopharmaceuticals; Radiotherapy Dosage; Retrospective Studies; Risk Factors; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden; Yttrium Radioisotopes | 2014 |
Yttrium-90 radioembolization stops progression of targeted breast cancer liver metastases after failed chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Embolization, Therapeutic; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Radiopharmaceuticals; Retrospective Studies; Risk Factors; Time Factors; Treatment Failure; Yttrium Radioisotopes | 2014 |
Use of PERCIST for Prediction of Progression-Free and Overall Survival After Radioembolization for Liver Metastases from Pancreatic Cancer.
Topics: Aged; Aged, 80 and over; Algorithms; Disease Progression; Disease-Free Survival; Embolization, Therapeutic; Female; Fluorodeoxyglucose F18; Humans; Liver Neoplasms; Male; Microspheres; Middle Aged; Pancreatic Neoplasms; Predictive Value of Tests; Radiopharmaceuticals; Survival Analysis; Treatment Outcome; Yttrium Radioisotopes | 2016 |
Outcomes of Radioembolization in the Treatment of Hepatocellular Carcinoma with Portal Vein Invasion: Resin versus Glass Microspheres.
Topics: Aged; alpha-Fetoproteins; Aspartate Aminotransferases; Bilirubin; Carcinoma, Hepatocellular; Disease Progression; Embolization, Therapeutic; Female; Glass; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Microspheres; Middle Aged; Neoplasm Invasiveness; New York City; Portal Vein; Proportional Hazards Models; Radiopharmaceuticals; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome; Venous Thrombosis; Yttrium Radioisotopes | 2016 |
Yttrium-90 Radioembolization of Advanced, Unresectable Breast Cancer Liver Metastases-A Single-Center Experience.
Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Disease Progression; Embolization, Therapeutic; Female; Germany; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Middle Aged; Multivariate Analysis; Palliative Care; Proportional Hazards Models; Radiopharmaceuticals; Risk Factors; Time Factors; Treatment Outcome; Yttrium Radioisotopes | 2016 |
Yttrium-90 Radioembolization for Breast Cancer Liver Metastases.
Topics: Breast Neoplasms; Disease Progression; Embolization, Therapeutic; Female; Humans; Liver Neoplasms; Palliative Care; Radiopharmaceuticals; Risk Factors; Time Factors; Treatment Outcome; Yttrium Radioisotopes | 2016 |
Neurokinin A monitoring of response to interferon alpha in a patient with an advanced small bowel neuroendocrine tumour uncontrolled by somatostatin analogue therapy.
Topics: Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Carcinoid Tumor; Disease Progression; Drug Monitoring; Female; Humans; Interferon-alpha; Intestinal Neoplasms; Liver Neoplasms; Middle Aged; Neoplasm Staging; Neuroendocrine Tumors; Neurokinin A; Somatostatin; Yttrium Radioisotopes | 2017 |
Bridging Locoregional Therapy Prolongs Survival in Patients Listed for Liver Transplant with Hepatocellular Carcinoma.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Combined Modality Therapy; Disease Progression; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Staging; Retrospective Studies; Tissue and Organ Procurement; Waiting Lists; Young Adult; Yttrium Radioisotopes | 2017 |
Prognostic value of pre-treatment F-18-FDG PET-CT in patients with hepatocellular carcinoma undergoing radioembolization.
Topics: Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Chi-Square Distribution; Disease Progression; Disease-Free Survival; Embolization, Therapeutic; Female; Florida; Fluorodeoxyglucose F18; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Microspheres; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Positron Emission Tomography Computed Tomography; Predictive Value of Tests; Proportional Hazards Models; Radiopharmaceuticals; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome; Yttrium Radioisotopes | 2016 |
A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Disease Progression; Embolization, Therapeutic; Female; Follow-Up Studies; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Staging; Patient Selection; Retrospective Studies; Treatment Outcome; Yttrium Radioisotopes | 2009 |
Selective internal radiation therapy with SIR-spheres for the treatment of unresectable colorectal hepatic metastases.
Topics: Colorectal Neoplasms; Disease Progression; Female; Humans; Liver Neoplasms; Male; Microspheres; Middle Aged; Radiography, Interventional; Radiotherapy Dosage; Survival Rate; Tomography, Emission-Computed; Tomography, X-Ray Computed; Treatment Outcome; Yttrium Radioisotopes | 2009 |
Harnessing the energy: development of radioimmunotherapy for patients with non-Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal; Disease Progression; Disease-Free Survival; Humans; Immunotoxins; Lymphoma, Non-Hodgkin; Radioimmunotherapy; Survival Rate; Treatment Outcome; Yttrium Radioisotopes | 2009 |
Analysis of prognostic factors after yttrium-90 radioembolization of advanced hepatocellular carcinoma.
Topics: Aged; alpha-Fetoproteins; Analysis of Variance; Carcinoma, Hepatocellular; Disease Progression; Embolization, Therapeutic; Female; Humans; Liver Neoplasms; Male; Microspheres; Middle Aged; Patient Selection; Prognosis; Radionuclide Imaging; Radiopharmaceuticals; Retrospective Studies; Survival Analysis; Technetium Tc 99m Aggregated Albumin; Tumor Burden; Yttrium Radioisotopes | 2010 |
Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Clinical Trials, Phase II as Topic; Disease Progression; Embolization, Therapeutic; Female; Humans; Liver Neoplasms; Male; Microspheres; Middle Aged; Neoplasm Staging; Radiopharmaceuticals; Randomized Controlled Trials as Topic; Standard of Care; Treatment Outcome; Yttrium Radioisotopes | 2011 |
Peptide receptor radioligand therapy is an effective treatment for the long-term stabilization of malignant gastrinomas.
Topics: Adult; Aged; Aged, 80 and over; Disease Progression; Female; Gastrinoma; Humans; Lutetium; Male; Middle Aged; Neoplasm Metastasis; Octreotide; Radioisotopes; Receptors, Peptide; Retrospective Studies; Tomography, X-Ray Computed; Treatment Outcome; Yttrium Radioisotopes | 2011 |
Transarterial hepatic yttrium-90 radioembolization in patients with unresectable intrahepatic cholangiocarcinoma: factors associated with prolonged survival.
Topics: Aged; Aged, 80 and over; Angiography; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biomarkers, Tumor; CA-19-9 Antigen; Cholangiocarcinoma; Disease Progression; Embolization, Therapeutic; Female; Fluoroscopy; Humans; Liver Function Tests; Liver Neoplasms; Magnetic Resonance Imaging; Male; Microspheres; Middle Aged; Retrospective Studies; Survival Rate; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; Treatment Outcome; Yttrium Radioisotopes | 2012 |
Altered biodistribution of somatostatin analogues after first cycle of Peptide receptor radionuclide therapy.
Topics: Adult; Disease Progression; Female; Humans; Indium Radioisotopes; Intestinal Neoplasms; Liver Neoplasms; Lymphatic Metastasis; Magnetic Resonance Imaging; Neoplasm Metastasis; Neuroendocrine Tumors; Octreotide; Positron-Emission Tomography; Radioisotopes; Receptors, Peptide; Somatostatin; Tomography, X-Ray Computed; Yttrium Radioisotopes | 2011 |
Repeated cycles of peptide receptor radionuclide therapy (PRRT)--results and side-effects of the radioisotope 90Y-DOTA TATE, 177Lu-DOTA TATE or 90Y/177Lu-DOTA TATE therapy in patients with disseminated NET.
Topics: Aged; Diagnostic Imaging; Disease Progression; Female; Humans; Lutetium; Male; Middle Aged; Neoadjuvant Therapy; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Radioisotopes; Receptors, Peptide; Statistics, Nonparametric; Treatment Outcome; Tumor Burden; Yttrium Radioisotopes | 2012 |
Treating and downstaging hepatocellular carcinoma in the caudate lobe with yttrium-90 radioembolization.
Topics: Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Disease Progression; Embolization, Therapeutic; Feasibility Studies; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Rate; Treatment Outcome; Yttrium Radioisotopes | 2012 |
Yttrium-90 radioembolization of renal cell carcinoma metastatic to the liver.
Topics: Aged; Brachytherapy; Carcinoma, Renal Cell; Disease Progression; Embolization, Therapeutic; Female; Humans; Kidney Neoplasms; Liver Neoplasms; Male; Microspheres; Middle Aged; Positron-Emission Tomography; Radiation Dosage; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Yttrium Radioisotopes | 2012 |
Radioembolisation with (90)Y-labelled resin microspheres in the treatment of liver metastasis from breast cancer.
Topics: Breast Neoplasms; Chemoembolization, Therapeutic; Disease Progression; Female; Humans; Liver Function Tests; Liver Neoplasms; Microspheres; Middle Aged; Survival Rate; Treatment Outcome; Yttrium Radioisotopes | 2013 |
Radioembolization for hepatocellular carcinoma with portal vein thrombosis: impact of liver function on systemic treatment options at disease progression.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Cohort Studies; Disease Progression; Embolization, Therapeutic; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Liver Cirrhosis; Liver Function Tests; Liver Neoplasms; Male; Middle Aged; Patient Selection; Portal Vein; Venous Thrombosis; Yttrium Radioisotopes | 2013 |
Radioembolization of the spleen: a revisited approach for the treatment of malignant lymphomatous splenomegaly.
Topics: Aged; Biopsy, Needle; Disease Progression; Embolization, Therapeutic; Fatal Outcome; Humans; Immunohistochemistry; Lymphoma; Male; Microspheres; Multimodal Imaging; Radiation Dosage; Radiopharmaceuticals; Spleen; Splenectomy; Splenomegaly; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; Yttrium Radioisotopes | 2013 |
Use of ibritumomab tiuxetan anti-CD20 radioimmunotherapy in a non-Hodgkin's lymphoma patient previously treated with a yttrium-90-labeled anti-CD22 monoclonal antibody.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD; Antigens, CD20; Antigens, Differentiation, B-Lymphocyte; B-Lymphocytes; Cell Adhesion Molecules; Disease Progression; Humans; Lectins; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Radioimmunotherapy; Radiopharmaceuticals; Sialic Acid Binding Ig-like Lectin 2; Treatment Outcome; Yttrium Radioisotopes | 2003 |
Yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin) induces long-term durable responses in patients with relapsed or refractory B-Cell non-Hodgkin's lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antigens, CD20; Disease Progression; Female; Humans; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Radioimmunotherapy; Recurrence; Retrospective Studies; Time Factors; Treatment Outcome; Yttrium Radioisotopes | 2005 |
Gamma camera scans and pretreatment tumor volumes as predictors of response and progression after Y-90 anti-CD20 radioimmunotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antigens, CD20; Disease Progression; Female; Gamma Cameras; Humans; Indium Radioisotopes; Lymphoma, B-Cell; Male; Middle Aged; Prognosis; Radioimmunotherapy; Radionuclide Imaging; Recurrence; Treatment Outcome; Yttrium Radioisotopes | 2005 |
Allogeneic hematopoietic cell transplantation following conditioning with 90Y-ibritumomab-tiuxetan.
Topics: Adult; Antibodies, Monoclonal; Antineoplastic Agents; Cyclophosphamide; Disease Progression; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Male; Radioimmunotherapy; Recurrence; Remission Induction; Retrospective Studies; Time Factors; Transplantation Conditioning; Treatment Outcome; Vidarabine; Yttrium Radioisotopes | 2006 |
Mid-term results in otherwise treatment refractory primary or secondary liver confined tumours treated with selective internal radiation therapy (SIRT) using (90)Yttrium resin-microspheres.
Topics: Brachytherapy; Disease Progression; Feasibility Studies; Female; Humans; Liver Neoplasms; Male; Microspheres; Neoplasm Staging; Survival Rate; Tomography, Emission-Computed; Tomography, X-Ray Computed; Treatment Outcome; Yttrium Radioisotopes | 2007 |
Unresectable chemorefractory liver metastases: radioembolization with 90Y microspheres--safety, efficacy, and survival.
Topics: Disease Progression; Female; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Magnetic Resonance Imaging; Male; Microspheres; Middle Aged; Prospective Studies; Survival Analysis; Tomography, Emission-Computed; Treatment Outcome; Yttrium Radioisotopes | 2008 |
Hemophilic synovitis of the knee and the elbow.
Topics: Adolescent; Adult; Arthroscopy; Child; Chronic Disease; Disease Progression; Elbow Joint; Endoscopy; Factor VIII; Follow-Up Studies; Gold Radioisotopes; Hemarthrosis; Hemophilia A; Humans; Injections, Intra-Articular; Joint Diseases; Knee Joint; Prospective Studies; Radiography; Radiopharmaceuticals; Radius; Recurrence; Synovectomy; Synovitis; Treatment Outcome; Yttrium Radioisotopes | 1997 |